{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"}],"units":"Participants"}],"description":"Overall survival is assessed, without regard to disease status, post-transplant, at Day 100.","groups":[{"description":"Patients receiving Fludarabine, Busulfan, cyclophosphamide and post-transplant cyclophosphamide for a haploidentical donor transplant","id":"OG000","title":"Haploidentical Transplant"}],"paramType":"NUMBER","populationDescription":"20 patients received a haploidentical transplant and therefore are eligible to be evaluated for Day 100 survival","reportingStatus":"POSTED","timeFrame":"Day 100","title":"Overall Survival at Day 100","type":"SECONDARY","unitOfMeasure":"participants"}